Lucid Diagnostics Inc.
LUCD Nasdaq
SEC CIK 1799011
Follow Lucid Diagnostics
Weekly email: filings, results
Revenue, last quarter
$1.2M
−0.7% vs same quarter last year
Net income
−$6.7M
+35.8% vs same quarter last year
EPS, diluted
−$0.03
+70% vs same quarter last year
Operating cash flow
−$15.6M
−42.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $4.7M | −$58M |
| FY24 | $4.3M | −$45.5M |
| FY23 | $2.4M | −$52.7M |
| FY22 | $377K | −$56.2M |
| FY21 | $500K | −$28.1M |
| FY20 | - | −$8.3M |
| FY19 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | −41.7% | −1054.8% | −1232.7% |
| FY24 | −63.3% | −1059.6% | −1047.6% |
| FY23 | - | −1996.8% | −2169.1% |
| FY22 | 100% | −14920.7% | −14899.5% |
| FY21 | 100% | −5483.8% | −5615.6% |
| FY20 | - | - | - |
| FY19 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$46.7M |
| FY24 | −$44.4M |
| FY23 | - |
| FY22 | −$32.9M |
| FY21 | −$18.5M |
| FY20 | - |
| FY19 | - |
- Lucid Diagnostics
- Healthcare median
Show the numbers
| Year | Lucid Diagnostics | Healthcare median |
|---|---|---|
| FY25 | −1232.7% | −30.6% |
| FY24 | −1047.6% | −47% |
| FY23 | −2169.1% | −58% |
| FY22 | −14899.5% | −80.4% |
| FY21 | −5615.6% | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |